Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.70 USD
-0.01 (-0.90%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $0.70 0.00 (0.43%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 1 - 20 ( 390 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
2Q24 Results; Xpovio Sales Beat Expectations; Lower End of Guidance Range Raised for 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Solid Update From SIENDO Study in TP53 Wild-Type Endometrial Cancer Patients Presented at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
1Q24 Results; All Eyes on Three Pivotal Phase 3 Studies Anticipated to Read Out in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
4Q23 Results; Data From Three Phase 3 Pivotal Studies Expected in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
FY23 Preliminary Revenues Disappoint, But Focus Should be on New Indications in the Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ASH 2023 Weekend Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Updated Overall Survival Data For Xpovio in TP53 Wild-Type Endometrial Cancer Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ASH 2023 Abstract Round Up for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
3Q23 Results; Xpovio Sales Slightly Above Our Expectations; Investor Focus Should Be on Ongoing Phase 3 Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Clinical Trial Agreement With BMY For Mezigdomide in Combination With Xpovio and Dexamethasone in r/r MM Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
2Q23 Results; Key Data Readouts Expected in 2024 and 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
As XPOVIO Demand Grows, Revenue Remains Flat
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Updated Data From SIENDO Study Subgroup Analysis of Xpovio in TP53 WT Endometrial Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
A While to Wait for SIENDO to Help Selinexor''s Sluggish Sales
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D